More study data available!
Data has been uploaded for 5 studies including:
- Clinical trials:
- HVTN 097 evaluates prime/boost regimens using combinations of ALVAC-HIV (vCP1521), AIDSVAX B/E, and bivalent subtype C gp120/MF59,
- HVTN 105 evaluates prime/boost regimens using DNA-HIV-PT123 and AIDSVAX B/E (with DNA both as a prime and a boost),
- CAVD 653/EV06 evaluates the combination of DNA-HIV-PT123 and AIDSVAX B/E in participants with or without underlying Schistosoma mansoni infection.
- Pre-clinical studies:
- Pettit studies (CAVD 649 and CAVD 650) comparing variants of the broadly neutralizing antibodies (bnAbs),10-1074 and 3BNC117, in order to evaluate potential effects on the functioning of the LS mutation.
Click on the study page links below for Protocol Team reports, data summaries, and more details about the studies.
Data was uploaded for the following studies:
|
Name & Description |
Data Added |
Type |
PI |
Strategy |
|
HVTN 097 is a Phase Ib clinical trial to evaluate the safety and immunogenicity of prime/boost regimens using combinations of ALVAC-HIV (vCP1521), AIDSVAX B/E, and bivalent subtype C gp120/MF59. |
BAMA, ICS, NAB |
Phase Ib |
Glenda Gray |
Combo: DNA, protein & vector vaccines |
|
HVTN 105 is a Phase Ib clinical trial to evaluate the safety and immunogenicity of combinations of DNA-HIV-PT123 and AIDSVAX B/E. |
BAMA, ICS, NAB |
Phase I |
Mike Keefer |
Combo: DNA & protein vaccines |
|
CAVD 653 (EV06/TP026) is a clinical trial to investigating the impact of the S. mansoni infection on HIV vaccine safety and immune responses. |
BAMA, NAB |
Phase I |
Giuseppe Pantaleo |
Combo: DNA and protein vaccines |
|
CAVD 649 is a PK study in mice comparing variants of the broadly neutralizing antibody (bnAb), 10-1074, in order to evaluate potential effects on the functioning of the LS mutation. |
PK MAB |
Pre-Clinical Non-NHP |
Dean Pettit |
Prophylactic neutralizing Ab |
|
CAVD 650 is a PK study in mice comparing variants of the broadly neutralizing antibody (bnAb), 3BNC117, in order to evaluate potential effects on the functioning of the LS mutation. |
PK MAB |
Pre-Clinical Non-NHP |
Dean Pettit |
Prophylactic neutralizing Ab |